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Abstract
Background: The peritoneum is the second most common site of recurrence in colorectal cancer. Early detection
of peritoneal carcinomatosis (PC) by imaging is difficult. Patients eventually presenting with clinically apparent PC
have a poor prognosis. Median survival is only about five months if untreated and the benefit of palliative systemic
chemotherapy is limited. Only a quarter of patients are eligible for curative treatment, consisting of cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy (CR/HIPEC). However, the effectiveness depends highly on
the extent of disease and the treatment is associated with a considerable complication rate.
These clinical problems underline the need for effective adjuvant therapy in high-risk patients to minimize the risk
of outgrowth of peritoneal micro metastases. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) seems
to be suitable for this purpose. Without the need for cytoreductive surgery, adjuvant HIPEC can be performed with
a low complication rate and short hospital stay.
Methods/Design: The aim of this study is to determine the effectiveness of adjuvant HIPEC in preventing the
development of PC in patients with colon cancer at high risk of peritoneal recurrence. This study will be performed
in the nine Dutch HIPEC centres, starting in April 2015. Eligible for inclusion are patients who underwent curative
resection for T4 or intra-abdominally perforated cM0 stage colon cancer. After resection of the primary tumour, 176
patients will be randomized to adjuvant HIPEC followed by routine adjuvant systemic chemotherapy in the experimental
arm, or to systemic chemotherapy only in the control arm. Adjuvant HIPEC will be performed simultaneously or shortly
after the primary resection. Oxaliplatin will be used as chemotherapeutic agent, for 30 min at 42-43 °C. Just before HIPEC,
5-fluorouracil and leucovorin will be administered intravenously. Primary endpoint is peritoneal disease-free survival at
18 months. Diagnostic laparoscopy will be performed routinely after 18 months postoperatively in both arms of the
study in patients without evidence of disease based on routine follow-up using CT imaging and CEA.
(Continued on next page)
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Discussion: Adjuvant HIPEC is assumed to reduce the expected 25 % absolute risk of PC in patients with T4 or
perforated colon cancer to a risk of 10 %. This reduction is likely to translate into a prolonged overall survival.
Trial registration number: NCT02231086 (Clinicaltrials.gov)
Keywords: Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC), Colon cancer, Peritoneal carcinomatosis (PC)
Background
Colorectal cancer (CRC) is the third most common cancer
in the world. In 2012, almost 1.4 million new patients
were diagnosed, with an expected incidence of 2.4 million
in 2035 [1]. The peritoneum is the second most common
site of recurrence in patients with CRC, accounting for 25
to 35 % of all recurrences [2, 3]. Because the clinical
diagnosis of peritoneal carcinomatosis (PC) is much more
difficult than the diagnosis of liver or lung metastases, it is
likely that reported incidences of metachronous PC are
underestimated. Important risk factors for peritoneal
tumour seeding of CRC identified in the literature are
advanced stage of the primary tumour (pT4) and tumour
perforation [4–7].
PC of colorectal cancer origin is associated with a poor
prognosis. Median survival is only about 5 months if
untreated and has a reported range between 5 and
15 months if treated with palliative systemic therapy, being
significantly worse compared to survival rates after
palliative systemic therapy for non-peritoneal localizations
[8–11]. Quality of life is often significantly impaired
because of ascites and bowel obstruction [11]. In three
quarters of the patients with PC of colorectal origin, only
palliative treatment options remain at time of diagnosis
[12]. In the remaining quarter of the patients without
distant metastases and restricted peritoneal tumour load,
cytoreductive surgery (CR) and HIPEC is an intentionally
curative treatment option. A large number of phase II
studies and two phase III trials have been published on
CR/HIPEC, showing an improved survival in comparison
with systemic chemotherapy only [8, 13–24]. However,
the effectiveness of CR/HIPEC highly depends on the
extent of disease. If complete cytoreduction of PC is
obtained, 5-year survival rates of 45 to 51 % can be
achieved in combination with HIPEC, but survival is
significantly lower if not all visible tumour could be
resected [25, 26]. Furthermore, CR/HIPEC is associated
with substantial morbidity, namely infectious complications
and abdominal wall complications.
Because of the difficulties in treating PC at a clinically
overt stage and the restricted sensitivity of imaging modal-
ities to detect PC at an early stage, advancing the treatment
to a subclinical stage may overcome the current problems
in treating patients with PC of colorectal origin. In other
words, effective adjuvant treatment to prevent develop-
ment of PC in high-risk CRC patients is warranted.
Intraperitoneal administration of chemotherapy has been
used to treat or prevent PC from various primary malig-
nancies [19, 27–34]. From a pharmacological point of view,
this is an attractive approach given the peritoneal-plasma
barrier, which allows for higher peritoneal cavity concen-
trations resulting in higher efficacy while systemic toxicity
is not increased.
In an attempt to prevent PC of colorectal origin,
intraperitoneal 5-FU administration (IPEC) through a
peritoneal catheter in the immediate postoperative
period or as prolonged treatment up to 12 months
has been used, as well as HIPEC using mitomycin-C or
oxaliplatin [31, 32, 35–38]. It can be concluded from these
studies that intraperitoneal chemotherapy seems to reduce
intraperitoneal recurrence rates, and that even a survival
benefit is suggested in studies using adjuvant HIPEC [39].
These studies are subjected to significant bias and no
definitive conclusions can be drawn based on these
data. With regard to treatment-related morbidity of
adjuvant (H)IPEC, these data, as well as experience
from the first 10 patients included in a Dutch feasibility
study, reveal that adjuvant HIPEC is a well-tolerated
intervention with no significant morbidity, which can be
performed in a short stay setting [39, 40]. This supports
conducting a randomized trial to determine the oncological
effectiveness of adjuvant HIPEC in addition to routine
adjuvant systemic therapy.
Methods/Design
Objective
The primary aim of this study is to determine the
oncological effectiveness of adjuvant HIPEC using oxali-
platin, following a curative resection of a T4 or intra-
abdominally perforated colon carcinoma in preventing the
development of PC.
Secondary aims are:
1. to determine the incidence of PC in pT4 and
perforated colon cancer with metastatic patterns
based on prospectively collected data and diagnostic
laparoscopy at 18 months as a golden standard
during follow-up;
2. to identify molecular parameters in tissues of primary
tumours indicating high-risk of developing PC;
3. to determine treatment-related morbidity of open
and laparoscopic adjuvant HIPEC;
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4. to determine treatment-related morbidity of
simultaneous and staged adjuvant HIPEC
(both early postoperative (0–10 days) as well
as delayed (5–8 weeks));
5. to determine several procedural characteristics of
adjuvant HIPEC such as operating time, hospital
stay, and re-admission rate;
6. to compare quality of life and costs of adjuvant
HIPEC with standard adjuvant systemic treatment.
Design
This will be a randomized controlled clinical trial of
the Dutch Colorectal Cancer Group (DCCG) that will be
performed in the nine Dutch HIPEC centres, starting in
April 2015. Eligible patients will be randomized (in a 1:1
ratio) to adjuvant HIPEC followed by standard adjuvant
systemic chemotherapy in the experimental arm, or
adjuvant systemic chemotherapy alone in the control
arm (Fig. 1). Stratification factors will be tumour
characteristic (T4 or perforation), surgical approach of
the primary tumour resection (laparoscopy or open)
and age (<65 years or ≥65 years).
Timing of adjuvant HIPEC is tailored to the different
clinical entities within the study population. Patients with
obvious clinical T4 stage can be asked preoperatively for
informed consent with simultaneous HIPEC if randomized
in the experimental arm. If patients are randomized
postoperatively based on intra-operative findings, early
staged adjuvant HIPEC is preferably performed as soon as
possible after primary resection but at a maximum of
10 days. When early postoperative HIPEC is not feasible,
delayed staged adjuvant HIPEC will be performed in week
Fig. 1 Flow-diagram COLOPEC trial. HIPEC: hyperthermic intraperitoneal chemotherapy
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5 to 8 from primary resection. Adjuvant HIPEC can be
performed either by laparoscopy or open approach. Subse-
quently, patients will receive routine adjuvant systemic
chemotherapy according to local treatment protocols
within 3 weeks from HIPEC, preferably as soon as the clin-
ical condition allows for systemic therapy. Follow-up will
be performed routinely according to the national guideline
during the first 18 months. Patients who already developed
recurrent disease during this time interval will be treated
accordingly. During the entire postoperative period,
concomitant medications, adverse events, procedures and
adjuvant therapies will be reviewed and documented. In
patients who have no clinical signs of recurrent disease at
18 months on CT scan of the thorax and abdomen in
combination with non-elevated CEA levels, diagnostic
laparoscopy will be performed in both arms of the study.
Laparoscopy enables accurate assessment of the primary
endpoint of the study and may have therapeutic implica-
tions for patients in whom asymptomatic PC is proven by
laparoscopically taken biopsies. These patients will subse-
quently be treated by CR/HIPEC according to the national
guideline if fulfilling the treatment criteria, with a switch to
mitomycin-C in patients who underwent adjuvant HIPEC
with oxaliplatin previously. The staging laparoscopy at
18 months is supported by the increasing data in the litera-
ture on the value of second look surgery for high-risk
patients [41, 42]. Patients with a negative laparoscopy will
continue routine follow-up for at least 5 years from primary
resection and during this period, oncological outcome in
terms of local recurrence, metastases and survival as well as
oncological therapies will be documented. All relevant data
during work up, management and follow up will be
collected in an electronic case record form. In addition,
quality of life and economic evaluation questionnaires will
be administered to the patient at each follow-up interval.
Data will be documented in line with ‘Good Clinical
Practice’ and Dutch legal requirements.
Study population
Patients diagnosed with adenocarcinoma of the colon
and either one of the two following risk factors for PC
or both will be considered for inclusion:
 T4N0-2M0, either consisting of obvious clinical T4
stage based on preoperative imaging or
intraoperative findings, or pathological T4 stage;
 primary tumour presenting with perforation being
curatively resected (N0-2 M0 stage).
Those patients are eligible for this study when they
meet the following inclusion criteria:
 age between 18 and 75 years;
 intention to start adjuvant systemic therapy;
 adequate clinical condition to undergo simultaneous
HIPEC, or re-laparoscopy/laparotomy with HIPEC
within either 10 days or between week 5–8 from
primary resection;
 white blood cell count of at least 3000/mm3,
platelet count of at least 100.000/mm3;
 normal creatinine or creatinine clearance of at least
50 ml/min;
 written informed consent.
A potential subject who meets any of the following
criteria will be excluded from participation in this study:
 postoperative complications that interfere with
adjuvant HIPEC within 8 weeks (i.e. persisting
intra-abdominal abscess, significant fascial dehiscence,
enteric fistula);
 non-curative intent of treatment;
 liver and/or lung metastases;
 pathological T4N0M0 stage with microsatellite
instability;
 unstable or uncompensated respiratory or cardiac
disease;
 severe hepatic or renal dysfunction;
 bleeding diathesis or coagulopathy.
Treatment strategies
Standard care of the control arm
Treatment in the control arm of the COLOPEC trial is in
accordance with the Dutch guideline for adjuvant chemo-
therapy in colon cancer patients (www.oncoline.nl). First
line adjuvant systemic chemotherapy for colon cancer
consists of six months treatment with capecitabin and
oxaliplatin (CAPOX) every three weeks or 5-FU and
oxaliplatin (FOLFOX) every two weeks. Adjuvant chemo-
therapy is preferably started within six to eight weeks after
primary surgery and at a maximum of 12 weeks after
primary resection.
Investigational treatment of the experimental arm
Treatment in the experimental arm consists of adjuvant
HIPEC followed by standard systemic chemotherapy.
HIPEC can be performed either by a laparoscopic or open
approach to the discretion of the surgeon.
1. Laparoscopic adjuvant HIPEC
Minimally invasive access to the abdominal cavity is
obtained, followed by adhesiolysis if indicated and
thorough inspection of the peritoneal surfaces. At
least one multiperforated inflow catheter is placed
through a 10–12 mm port in Douglas pouch with at
least one multiperforated outflow catheter in the right
subphrenic space. The patient’s body temperature will
be monitored in the oesophagus. All trocars are
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tightly fixed to the skin to avoid fluid leakage during
the procedure. Perfusion by an auto regulated pump
system will be started with a minimum of 2 L isotonic
dialysis fluid at a flow rate of 1-2 L/min and an inflow
temperature of 42-43 °C. Before the beginning of
HIPEC, fluorouracil 400 mg/m2 and leucovorin
20 mg/m2 will be administered intravenously to
potentiate oxaliplatin activity. After attaining at least
42 °C inflow temperature, oxaliplatin (460 mg/m2)
will be added to the circuit in a single dose. The
operating table will be rotated and tilted every 5 min,
and the abdomen will be agitated throughout the
infusion to allow homogeneous exposure of the
peritoneal surfaces to the heated chemotherapy.
After a total perfusion time of 30 min, the peritoneal
fluid is totally suctioned and the abdomen is examined
for evidence of tissue injury or bleeding. A suction
drain will be left in Douglas pouch for 24 h. The
other port sites are closed in a standard fashion.
Postoperative care after simultaneous HIPEC will be
according to the primary colonic resection following an
enhanced recovery program. After staged laparoscopic
HIPEC, patients are fully mobilized at day one with
normal diet and will intentionally be discharged at day
one to three if the institutional discharge criteria are
fulfilled. Hematologic parameters will be determined at
day 14, followed by start of systemic chemotherapy.
2. Open adjuvant HIPEC
Open adjuvant HIPEC can be performed
simultaneously in patients undergoing primary
open resection, and staged open adjuvant HIPEC
can be performed by re-laparotomy in patients
who underwent primary open CRC resection. The
decision to perform staged open or laparoscopic
HIPEC in case of prior open resection will be left
to the discretion of the surgeon. Besides the
access to the peritoneal cavity, the procedure is
similar to the laparoscopic approach as described
above. Preferably, a closed perfusion is performed
rather than a Colosseum technique to have similar
pharmacokinetics as a laparoscopic approach. After
positioning of the in- and outflow catheters, the
abdomen will then be closed and subsequently
perfusion will be started. Postoperative care is similar
to the laparoscopic approach with an anticipated day
of discharge between day two to five if discharge
criteria are fulfilled. Hematologic parameters will be
determined at day 14, followed by start of systemic
chemotherapy.
Main outcome
The primary endpoint of the study is peritoneal recurrence-
free survival at 18 months determined by CTand if negative
by laparoscopy.
Secondary study endpoints
 treatment-related toxicity of adjuvant HIPEC,
including 30-day complication rate, re-intervention
rate, and re-admission rate;
 hospital stay for simultaneous and staged HIPEC,
either open or laparoscopic;
 3 and 5-year disease-free survival and overall survival;
 quality of life (EORTC-30, EORTC-CR29);
 costs (general, per year free of PC, per quality
adjusted life year) (EQ-5D-5 L, iMTA MCQ and
iMTA PCQ, adapted to the current study setting
and target population).
Additional outcome measures
 incidence of PC;
 sensitivity of imaging to detect PC during
follow-up, using laparoscopy as a golden standard;
 inter- and intra-variability amongst radiologists in
detecting PC using CT-imaging;
 differences in patterns of dissemination
(peritoneal plus or minus distant metastases);
 impact of adjuvant HIPEC on the degree of adhesions
and extent of adhesiolysis required at 18 months;
Sample size calculation
Approximately 25 % of CRC patients with a pT4 or
perforated primary tumour is expected to develop PC
(see below). Adjuvant HIPEC is expected to result in
a 60 % relative risk reduction in peritoneal recurrence
based on the currently available literature (see below). To
detect an absolute 15 % difference in PC recurrence-free
survival at 18 months (90 % peritoneal recurrence-free
under HIPEC plus systemic chemotherapy against 75 %
peritoneal recurrence free under systemic chemotherapy),
a total number of 176 patients (88 in each arm) is needed
(Kaplan-Meier, one-sided, alpha = 0.05, power of 80 %,
drop-out 5 %). Actually, the power may even be higher,
because the calculation ignores longer follow-up for the
patients who have been included early on in the study.
Data-analysis
The primary endpoint, peritoneal recurrence-free survival
at 18 months, will be compared between the two study
groups, using Kaplan Meier survival analysis with log rank
test and a significance level of 0.05.
Secondary study endpoints
Treatment effects will be expressed as a relative risk with
95 % confidence interval. Any binary secondary outcome
measures (e.g. re-operation rate, mortality rate, etc.) will
be analysed by using a Fisher’s exact or Chi-square test
with a two-sided significance level of 0.05 on an intention
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to treat basis. Continuous variables will be analysed by
independent samples t-test. Quality of life data will be
assessed using the questionnaires ‘EORTC-QLQ-C30’
and ‘CR 29’. The EORTS-QLQ-C30 is a questionnaire
developed to test global quality of life in cancer patients. In
addition, the EORTC-QLQ-CR29 focusses on colorectal
cancer patients. Results will be graphically represented
across all time points and analysed using a repeated
measures analysis of variance. All analyses will be intention
to treat. A p-value of <0.05 will be considered statistically
significant. Subgroup analyses will employ a test of inter-
action to explore whether there is evidence that the treat-
ment effects differ across subgroups. As with all subgroups
analyses, these will be interpreted with caution, and will be
considered hypothesis generating.
Economic evaluation
The economic evaluation of adjuvant HIPEC followed
by systemic chemotherapy against adjuvant systemic
chemotherapy alone will be performed from the societal
perspective as a cost-effectiveness as well as cost-utility
analysis. The primary outcomes will be the costs per
year free of PC and the costs per quality adjusted life
year (QALY) respectively. Incremental cost-effectiveness
and cost-utility ratios will be calculated for these outcomes,
along with 95 % confidence intervals based on non-
parametric bootstrapping to account for sampling variation.
Explorative subgroup analyses will be done for patients
presenting with or without perforation and for patients with
early (simultaneous/<10 days postoperatively) or delayed
(5–8 weeks postoperatively) HIPEC. Sensitivity analyses will
be performed for the unit costs of adjuvant HIPEC and for
alternative health valuation algorithms (see below).
Results will be displayed graphically with cost-effectiveness
planes and cost-effectiveness acceptability curves for
willingness-to-pay values up to €100,000.
The cost analysis will include all direct and indirect
medical and non-medical costs. Data on volumes will
be gathered from case reports forms, hospital information
systems and with short patient questionnaires at quar-
terly intervals during follow-up. The iMTA Medical
Consumption Questionnaire and iMTA Productivity Cost
Questionnaire, adapted to the current study setting and
target population, will be used.
Dissemination of cancer to the peritoneum may debilitate
a person’s quality of life on top of recovering from surgery
for the primary cancer. In addition to the already
mentioned cancer specific EORTC-QLQ-C30 and CR 29
questionnaires, patients will be asked to complete the
short EQ-5D-5L (Euroqol) generic health status question-
naire at each follow-up time point in order to gather
health status profiles over time that can be transposed into
QALYs using health utility scoring algorithms available
from the literature [43, 44] These algorithms reflect
preferences in the general population, which were elicited
with time trade-off elicitation techniques.
Also, a budget impact analysis (BIA) will be performed
linking data on disease incidence and prevalence, on
inclusion criteria, and on health care expenses per case.
Both governmental and health care insurer perspectives
will be addressed.
Safety
The medical ethical committee of the Academic Medical
Center Amsterdam has approved the study protocol
(MEC 2014–264, NL49960.018.14) and this study will be
conducted according to the principles of the Declaration
of Helsinki (Fortaleza, October 2013) and in accordance
with the Medical Research Involving Human Subjects
Act (WMO). An interim review will be performed after
inclusion of 25, 50 and 100 (of the total of 176 patients).
At 6 weeks after inclusion of these patients the trial’s safety
data will be evaluated. The data and safety monitoring
board (DSMB) will be supplied with the number of
(serious) adverse events in both groups at this time
point. If there is a skewed distribution of the number
of (serious) adverse events between the two groups an
efficacy analysis can be performed at the discretion of the
DSMB. Following these interim analyses the DSMB will
advise upon continuation of the trial.
Discussion
Rationale for HIPEC design; chemotherapeutic agent,
surgical approach and timing
In the COLOPEC trial we will use oxaliplatin as standard
chemotherapeutic agent for HIPEC. In the Netherlands, we
have recently switched from mitomycin-C as the standard
agent for HIPEC to oxaliplatin in all HIPEC centres.
Oxaliplatin and mitomycin-C are both cell cycle inde-
pendent alkylating agents, interfering with DNA and
DNA-synthesis. Because of a large molecular weight, there
is limited systemic absorption of both agents. The
enhancement of cytotoxicity under hyperthermia and a
maximal tissue penetration of 2 mm. are also comparable.
Although there are no randomized studies comparing
oxaliplatin and mitomycin-C for CR/HIPEC, the literature
suggests an equal antitumor effectiveness [45]. The
advantage of oxaliplatin is the absence of neutropenia
and shorter perfusion time (30 versus 90 min.) compared
to mitomycin-C.
In this project, there is the possibility to deliver HIPEC
by both the conventional open approach and a minimally
invasive approach. If compared to an open procedure,
laparoscopic HIPEC avoids the risk and recovery time
associated with a laparotomy while the temperature
profiles and peritoneal perfusion flow rates are similar [46].
Experimental studies in pigs suggest even better penetration
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of chemotherapy in a closed abdomen probably due to
increased abdominal pressure [47, 48].
Prophylactic resection of organs at risk of harbouring
tumour cells, such as omentectomy and ovariectomy,
has been performed in addition to adjuvant HIPEC [49].
There is currently no evidence to support this. Because
HIPEC is applied in adjuvant setting with the majority of
patients not expected to benefit from this intervention, we
aim to minimise invasiveness of the therapy. Therefore,
we decided not to perform prophylactic omentectomy,
ovariectomy or any other prophylactic surgery . Moreover,
we hypothesise that potential micro metastases at these
sites are sufficiently treated with HIPEC .
Timing of the adjuvant HIPEC procedure will be
tailored to the individual patient within the COLOPEC
trial. Both a simultaneous and a staged approach can be
chosen. A theoretical disadvantage of a staged approach is
the suggested phenomenon of residual cancer cells being
encapsulated with fibrin, which probably makes these cells
less accessible for chemotherapy at an interval of more
than two weeks after surgery [20, 50–52]. Therefore, it is
often stated that HIPEC should ideally be performed
simultaneously with primary tumour resection, although
this is not an evidence-based recommendation. Simultan-
eous adjuvant HIPEC is often not feasible because pT4 stage
is only found at definitive pathology, HIPEC is not available
at time of primary tumour resection in an emergency set-
ting for a perforated tumour, or primary resection is being
performed outside a HIPEC centre. In order to make results
from a RCT transferable to daily clinical practice in the end,
the possibility of early postoperative HIPEC has been
included in the study protocol. Staged HIPEC may be per-
formed within 10 days in case of adequate patient condition
and logistics, or may be delayed to 5–8 weeks from primary
resection. The theoretical advantage of staged adjuvant
HIPEC is that healing of the anastomosis is not compro-
mised by immunosuppression as a result of the administra-
tion of chemotherapeutic agents, and the more favourable
logistics. Disadvantages of staged adjuvant HIPEC are the
necessity of adhesiolysis, the risk of suboptimal distribution
of chemotherapy in the abdominal cavity, and the potential
delay of routine adjuvant systemic treatment.
Primary endpoint
Although 3-year disease-free survival (3-years-DFS)
using CT imaging is a commonly used endpoint in adjuvant
setting, 18 month laparoscopy is more appropriate in this
trial because of the restricted sensitivity of imaging
modalities to detect PC at an early stage. Also, second look
surgery is increasingly applied in patients at high risk of
developing PC in- and outside trial setting. Positive findings
during laparoscopy may have therapeutic implications,
which justifies an invasive method to determine the primary
outcome parameter. It is likely that a significant reduction
in peritoneal recurrence rate at 18 months will eventually
translate into an overall survival benefit given the worse
prognosis associated with peritoneal dissemination.
Expected results and impact on clinical practice and
health care system
There needs to be a good balance between associated costs
and morbidity on one hand and effectiveness on the other
hand for an adjuvant treatment modality. For routine adju-
vant systemic chemotherapy in colon cancer, an absolute
survival benefit as low as 5 % is considered to be worth-
while despite duration of treatment for six months with
treatment related toxicity such as hand-foot syndrome.
Based on reported incidences of PC between 14 and
58 % for perforated tumours [41, 53, 54] and between 17
and 50 % for pT4 stage [55–58], the estimated incidence
of PC in the study population will be 25 %. Reported
incidences may have been underestimated because of
the inaccuracy of routine follow-up examinations to
detect PC and incomplete autopsy rates of patients who
died of CRC. The relative risk reduction in a compara-
tive study of 25 patients undergoing prophylactic HIPEC
compared to a 1:2 matched control group was 82 % [59].
Older randomized studies using intraperitoneal 5-FU
showed relative risk reductions of peritoneal recurrence
of 78 % [38] and 62 % in favour of the intraperitoneal
chemotherapy groups [37]. Based on these data, a conser-
vative expected relative risk reduction of adjuvant HIPEC
is 60 %. The expected advantage of the experimental
intervention is therefore an absolute reduction of 15 % in
PC (from 25 % to 10 %).
As a consequence of a 15 % absolute risk reduction,
from each cohort of 100 patients, 85 patients will undergo
an additional treatment without any benefit. This is only
acceptable if the associated morbidity is relatively low,
which appears to be so based on systematic review of the
literature and our own feasibility study [39, 40].
With regard to cost-effectiveness, additional costs of
routine adjuvant HIPEC should be weighed against
gained life years and reduced costs of patients in whom
PC has been prevented to develop. A 15 % reduction of
peritoneal recurrence is expected to result in at least a
5 % survival benefit, given the dismal prognosis associated
with development of PC and based on an update of the
study by Sammartino et al. [49]. Reduced costs may be
related to less expensive treatment for clinically manifest
PC, such as CR/HIPEC (approximately €50.000 per
procedure) and palliative systemic treatment including
expensive targeted agents such as bevacizumab (€2.400
per month per patient). Furthermore, reduced costs may
be related to a reduced use of other palliative treatment
modalities (ascites drainage, palliative surgery) and less
need for palliative care in a hospital or other institutional
setting, or at home.
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